Sanofi Is ‘Looking at Options’ for Weekly GLP-1, Zerhouni Says

Sanofi, France’s biggest drugmaker, is considering options for a once-weekly GLP-1 diabetes treatment, Elias Zerhouni, Sanofi’s global research and development chief, said.

“We’re looking at various options,” Zerhouni told analysts during a conference call today. He declined to comment further.

Sanofi will bring two projects into clinical development for biosimilar insulins in a bid to broaden its diabetes portfolio. The French company is facing competition in the insulin field from rivals including Novo Nordisk A/S and Eli Lilly & Co.

“They are not biosimilars of our own molecules,” Sanofi Chief Executive Officer Chris Viehbacher said during the conference call with reporters. He didn’t elaborate.

Sanofi’s top-selling Lantus insulin last year garnered 4.96 billion euros ($6.6 billion) in sales, the company said today. Results from two late-stage trials for a new formulation of Lantus, also known as insulin glargine, are expected in the second quarter, Sanofi also said.

To contact the reporter on this story: Albertina Torsoli in Paris at atorsoli@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.